Novartis: Lupus Erythematosus, Systemic trials
The registry lists 14 Lupus Erythematosus, Systemic studies with Novartis as lead sponsor. 2 are open to participants now and 2 have results posted.
Phase 1 5Phase 2 5Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)Not yet recruitingNCT07923747Phase 1
- Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).RecruitingNCT06133972Phase 3
- Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus NephritisTerminatedNCT04181762Phase 3Results posted
- Study the Efficacy and Safety of VAY736 and CFZ533 in SLE PatientsCompletedNCT03656562Phase 2Results posted
- A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)Active, not recruitingNCT06581198Phase 2
- Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune DiseasesWithdrawnNCT06411639Phase 1
- An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).Active, not recruitingNCT06335979Phase 1
- Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune DiseaseActive, not recruitingNCT06293365Phase 2
- An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus ErythematosusCompletedNCT05798117Phase 1/2
- Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)Active, not recruitingNCT05639114Phase 3
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active, not recruitingNCT05624749Phase 3
- Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VTerminatedNCT05268289Phase 2
- Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)TerminatedNCT05203419Phase 1
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive, not recruitingNCT05126277Phase 3